AI Accelerates Vaccine Development; Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Platform to Battle Coronaviruses, Acute Respiratory Syndromes
- Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases
- Predictive Oncology launches new AI platform in fight against new pathogens
- Artificial intelligence likely to help find COVID-19 vaccines and therapeutics
With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) just announced it was entering the fight against the latest scourge and is launching a new artificial intelligence platform to aid in vaccine and drug development to battle coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) (http://nnw.fm/3uS2j).
Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates.
“The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development,” HSC(TM) co-inventor Dr. Larry DeLucas stated in a news release (http://nnw.fm/3uS2j). DeLucas, who flew aboard NASA Space Shuttle mission STS-50 as a payload specialist, is now the director of the Center for Structural Biology at University of Alabama School of Medicine.
Global health experts predict an ever-increasing number of viral outbreaks like COVID-19, and POAI intends to be at the forefront of efforts to identify and aid in the development of new vaccines and therapeutics. Predictive Oncology has enjoyed a business relationship with InventaBioTech and through negotiations signed a letter of intent to acquire Soluble Therapeutics, its assets and, most importantly, its HSC(TM) Technology. The technology dovetails POAI’s efforts against cancer as the HSC(TM) machines can be used in the development of new cancer antibodies and vaccines and create new possibilities in the fight against new pathogens. Soluble Therapeutics has previously worked with many of the major pharmaceutical companies searching for a vaccine such as Gilead Sciences (NASDAQ: GILD), GlaxoSmithKline (NYSE: GSK), Pfizer, Bayer and others.
The HSC(TM) Instrument and underlying technology have been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.
The HSC(TM) Technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. Able to do more with less, the technology only requires milligrams of material, where a traditional formulation effort can require up to a gram. Two decades in the making, HSC Technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pathogens, battle cancers, and enhance the drug development process by rapidly optimizing protein solubility and stability. Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics’ technology directly addresses this obstacle.
Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a rapid AI discovery platform that quickly and cost-effectively identifies potential vaccines and therapeutic candidates as well as optimizing protein formulations for stability and higher protein concentrations using FDA approved ingredients.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases
- Predictive Oncology launches new AI platform in fight against new pathogens
- Artificial intelligence likely to help find COVID-19 vaccines and therapeutics
With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) just announced it was entering the fight against the latest scourge and is launching a new artificial intelligence platform to aid in vaccine and drug development to battle coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) (http://nnw.fm/3uS2j).
Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates.
“The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development,” HSC(TM) co-inventor Dr. Larry DeLucas stated in a news release (http://nnw.fm/3uS2j). DeLucas, who flew aboard NASA Space Shuttle mission STS-50 as a payload specialist, is now the director of the Center for Structural Biology at University of Alabama School of Medicine.
Global health experts predict an ever-increasing number of viral outbreaks like COVID-19, and POAI intends to be at the forefront of efforts to identify and aid in the development of new vaccines and therapeutics. Predictive Oncology has enjoyed a business relationship with InventaBioTech and through negotiations signed a letter of intent to acquire Soluble Therapeutics, its assets and, most importantly, its HSC(TM) Technology. The technology dovetails POAI’s efforts against cancer as the HSC(TM) machines can be used in the development of new cancer antibodies and vaccines and create new possibilities in the fight against new pathogens. Soluble Therapeutics has previously worked with many of the major pharmaceutical companies searching for a vaccine such as Gilead Sciences (NASDAQ: GILD), GlaxoSmithKline (NYSE: GSK), Pfizer, Bayer and others.
The HSC(TM) Instrument and underlying technology have been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.
The HSC(TM) Technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. Able to do more with less, the technology only requires milligrams of material, where a traditional formulation effort can require up to a gram. Two decades in the making, HSC Technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pathogens, battle cancers, and enhance the drug development process by rapidly optimizing protein solubility and stability. Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics’ technology directly addresses this obstacle.
Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a rapid AI discovery platform that quickly and cost-effectively identifies potential vaccines and therapeutic candidates as well as optimizing protein formulations for stability and higher protein concentrations using FDA approved ingredients.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
